Meeting
2023 ASCO Quality Care Symposium
Stomatitis in patients receiving EGFR-targeted therapy for non-small cell lung cancer: A population-based cohort study across the United States.
Authors
Chuan Lu
Harvard T.H. Chan School of Public Health, Boston, MA
Chuan Lu, Kevin Sheng-Kai Ma, Tina Y.J. Hsieh, Sheng-Yin Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Prospective Risk Assessment and Reduction
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 406)
DOI
10.1200/OP.2023.19.11_suppl.406
Abstract #
406
Poster Bd #
H16
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2020 ASCO Virtual Scientific Program
ctDNA levels before treatment predict survival in non-small cell lung cancer patients treated with a tyrosine kinase inhibitor.
First Author: Mariano Provencio-Pulla
Poster
2019 ASCO Annual Meeting
Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes.
First Author: Alexandra Pender
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu